COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,633 Articles (22,913 medRxiv, 8,720 bioRxiv)

Most recent first Previous |  Page 1112: Articles 11111-11120  | Next

Mutations in RBD of SARS-CoV-2 Omicron variant result stronger binding to human ACE2 protein
Lupala, C. S., Ye, Y., Chen, H., Su, X., Liu, H.
10.1101/2021.12.10.472102 — Posted: 2021-12-13
Quantification of nuclear transport inhibition by SARS-CoV-2 ORF6 using a broadly applicable live-cell dose-response pipeline
Yoo, T. Y., Mitchison, T.
10.1101/2021.12.10.472151 — Posted: 2021-12-13
Structure of the 5' untranslated region in SARS-CoV-2 genome and its specific recognition by innate immune system via the human oligoadenylate synthase 1
Bignon, E., Miclot, T., Terenzi, A., Barone, G., Monari, A.
10.1101/2021.12.10.472066 — Posted: 2021-12-13
Structural models of SARS-CoV-2 Omicron variant in complex with ACE2 receptor or antibodies suggest altered binding interfaces
Lubin, J. H., Markosian, C., Balamurugan, D., Pasqualini, R., Arap, W., Burley, S. K., Khare, S. D.
10.1101/2021.12.12.472313 — Posted: 2021-12-13
Present and future distribution of bat hosts of sarbecoviruses: implications for conservation and public health
Muylaert, R. L., Kingston, T., Luo, J., Vancine, M. H., Galli, N., Carlson, C., John, R. S., Rulli, M. C., Hayman, D. T. S.
10.1101/2021.12.09.471691 — Posted: 2021-12-13
Cell Surface SARS-CoV-2 Nucleocapsid Protein Modulates Innate and Adaptive Immunity
Lopez-Munoz, A. D., Kosik, I., Holly, J., Yewdell, J. W.
10.1101/2021.12.10.472169 — Posted: 2021-12-13
A qualitative mathematical model of immunocompetence with applications to SARS-CoV-2 immunity
Burgos-Salcedo, J.
10.1101/2021.12.08.471857 — Posted: 2021-12-13
Measuring the impact of COVID-19 vaccination and immunity waning: a modelling study for Portugal
Caetano, C., Morgado, M. L., Patricio, P., Leite, A., Machado, A., Torres, A., Pereira, J. F., Namorado, S., Sottomayor, A., Peralta, A., Nunes, B.
10.1101/2021.12.10.21267618 — Posted: 2021-12-13
Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2
Titov, A., Shaykhutdinova, R., Shcherbakova, O. V., Serdyuk, Y. V., Sheetikov, S. A., Zornikova, K. V., Maleeva, A. V., Khmelevskaya, A., Dianov, D. V., Shakirova, N. T., Malko, D. B., Shkurnikov, M., Nersisyan, S., Tonevitsky, A., Khamaganova, E. G., Ershov, A. V., Osipova, E. Y., Nikolaev, R. V., Pershin, D. E., Vedmedskia, V. A., Maschan, M., Ginanova, V. R., Efimov, G. A.
10.1101/2021.12.12.21267518 — Posted: 2021-12-13
Symptoms persisting after hospitalization for COVID-19: 12 months interim results of the COFLOW study
Bek, M., Berentschot, J. C., Heijenbrok, M., Huijts, S., van Genderen, M. E., Vlake, J. H., van Bommel, J., Aerts, J. G. J. V., Ribbers, G. M., van den Berg, R. J. G., Hellemons, M. E., CO-FLOW collaboration Group
10.1101/2021.12.11.21267652 — Posted: 2021-12-13

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).